BioPharma Dive July 19, 2021
Dive Brief:
- BioNTech, the German drug developer now best known for the coronavirus vaccine it developed in partnership with Pfizer, will buy a cancer cell therapy factory and related research from Gilead’s Kite Pharma unit.
- The deal, which was announced on Monday, reflects BioNTech’s continued commitment to its roots in cancer drug research, particularly cell-based immunotherapies. In January 2020, before the pandemic’s reach became apparent, the biotech bought Neon Therapeutics, which was working on similar technology.
- Kite Pharma, which Gilead acquired in August 2017, will receive an undisclosed amount from BioNTech for its T cell receptor discovery platform and clinical manufacturing facility in Gaithersburg, Maryland. BioNTech said it will offer jobs to all 50 site employees and plans to...
Today's Sponsors
Today's Sponsor